By Kate Linebaugh GE is ramping up its investment in personalized medicine, reflecting the burgeoning interest in using genetic information to help tailor treatments to individual patients. The conglomerate is buying ? for an undisclosed sum ? SeqWright , a Houston company that provides contract genomic sequencing. As pharmaceutical companies develop more targeted treatments for different diseases such as cancer, doctors need to know more about the particular biological traits of different cancers to figure out the most effective therapies to prescribe. That?s where GE hopes to come in, by developing technologies to better identify the genetic profile of cancers and other illnesses.? Last year, the conglomerate said it would spend $1 billion over the next five years to research and develop advanced cancer diagnostic technology and molecular-imaging capabilities, as well as produce biopharmaceuticals. Two years ago, GE paid $580 million for cancer-diagnostics company Clarient ? the foundation of its expansion into molecular diagnostics. SeqWright will provide more in-depth analysis of genomic sequencing through its ability to assess deeper chunks of genetic material, GE says. The deal will ?deepen the services we can provide to pharmaceutical companies,? Clarient CEO Carrie Eglinton-Manner tells the Health Blog. SeqWright will continue its contract work with pharma companies like Eli Lilly and Roche, which have used its technologies to identify variants in diseases ranging from psychiatric disorders to heart ailments.? The company also worked with the U.S. Department of Agriculture to map the complete genetic-coding sequences of 150 different avian-influenza viruses.
Read more from the original source:?
GE Ramps Up Investment in Personalized Medicine
cbs ncaa tournament peyton hillis marchmadness mike d antoni nba trade rumors 2012 ncaa tournament schedule
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন